KRONOS BIO INC. - COM

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

01 май 2025 05:30:00 Источник Nasdaq GlobeNewswire

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

18 мар 2025 13:01:00 Источник Nasdaq GlobeNewswire

Kronos Bio Announces CEO Transition and Reduction in Force

27 ноя 2024 04:30:00 Источник Nasdaq GlobeNewswire

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

14 ноя 2024 13:02:00 Источник Nasdaq GlobeNewswire

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

13 ноя 2024 13:05:00 Источник Nasdaq GlobeNewswire

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

05 ноя 2024 06:00:01 Источник Nasdaq GlobeNewswire

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

23 окт 2024 05:55:00 Источник Nasdaq GlobeNewswire

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

09 окт 2024 05:55:00 Источник Nasdaq GlobeNewswire

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

07 окт 2024 05:55:00 Источник Nasdaq GlobeNewswire

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

25 сен 2024 05:55:00 Источник Nasdaq GlobeNewswire

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

23 сен 2024 05:55:00 Источник Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Medical and Investor Conferences in September

03 сен 2024 05:55:00 Источник Nasdaq GlobeNewswire

Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update

08 авг 2024 13:15:00 Источник Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

23 июл 2024 13:15:00 Источник Nasdaq GlobeNewswire

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 май 2024 14:15:00 Источник Nasdaq GlobeNewswire

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

22 май 2024 13:30:00 Источник Nasdaq GlobeNewswire

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer 

21 май 2024 05:15:00 Источник Nasdaq GlobeNewswire

Kronos Bio Reports First-Quarter 2024 Financial Results

09 май 2024 13:05:00 Источник Nasdaq GlobeNewswire

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 13:01:00 Источник Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

21 мар 2024 04:05:00 Источник Nasdaq GlobeNewswire